subsidiary of Daiichi Sankyo Company Ltd

Belfort bounced back with a string of victories, including one of the most impressive performances in the history of the UFC at Ultimate Brazil, where he decimated Wanderlei Silva with his incredible hand speed.Belfort knocked Silva senseless :44 into the first round. Belfort has competed against the best of the best in both the UFC and Pride Fighting Championship. His career has been marred by inconsistent performances, but many think his drop in weight from 205 only makes him more lethal.Now, after knocking out MMA legend Matt Lindland last January, Belfort makes his return to the UFC.Prediction: Rich Franklin’s footwork and boxing skills should help him keep distance from the dangerous hands of Belfort. Belfort will use his pure athleticism and push the pace, trying to get in range to unload his wicked strikes. This is a must-see for all fight fans.Rich Franklin spoils Belfort’s return, winning via a Unanimous Decision.. TOKYO and INDIANAPOLIS, Feb 3 /PRNewswire-FirstCall/ The U.S.

Food andDrug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9to 0 that prasugrel, an investigational antiplatelet agent, should be approvedfor the treatment of patients with acute coronary syndromes (ACS) managed withan artery-opening procedure known as percutaneous coronary intervention (PCI),Daiichi Sankyo Company, Limited, (TSE: 4568), and Eli Lilly and Company (NYSE:LLY) announced today.The Advisory Committee voted unanimously that prasugrel should be approvedfor the treatment of patients with acute coronary syndromes undergoing PCI.The FDA is not bound by the committee's recommendation, but it takes itsadvice into consideration when reviewing new drug applications."We are very proud of the prasugrel data," said John Alexander M.D.,M.P.H., global head of research and development, Daiichi Sankyo Company,Limited."Today's scientific exchange set the stage for a potential FDAapproval of prasugrel, and the future availability of this significantscientific advancement for the treatment of ACS-PCI patients.""We will continue to work closely with the FDA as the agency moves towardan action on the new drug application for prasugrel," said J. Anthony Ware,M.D., Lilly vice president and cardiovascular/acute care platform leader forprasugrel."It is important for patients to have multiple treatment options,and currently, ACS patients undergoing PCI have few options.Today's vote bythe advisory committee members is a positive step for patients.""Prasugrel represents an important new option forpatients with ACS whoare managed with PCI," said lead TRITON-TIMI 38investigator Elliott Antman,M.D., director of the Samuel A. Levine CardiacUnit at Brigham and Women'sHospital (BWH) in Boston and senior investigatorwith BWH's TIMI Study Group."In a large head-to-head trial, TRITON, showed that prasugrel was superior toclopidogrel, the current standard of care. Results from the TRITON trial showed that prasugrel takenwith aspirin reduced the relative risk of the combined endpoint ofcardiovascular death, non-fatal heart attacks or non-fatal stroke by 19percent more than clopidogrel (Plavix(R)/Iscover(R)) taken with aspirin. Prasugrel works by inhibitingplatelet activation and subsequent aggregation by blocking the P2Y12 adenosinediphosphate (ADP) receptor on the platelet surface.

A central focus of Daiichi Sankyo's research and development arethrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmunedisorders.Equally important to the company are hypertension, hyperlipidemiaor atherosclerosis and bacterial infections. For more information, visit Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S.subsidiary of Daiichi Sankyo Company, Ltd.For more information on DaiichiSankyo, Inc., please visit Eli Lilly and CompanyLilly, a leading innovation-driven corporation, is developing a growingportfolio of first-in-class and best-in-class pharmaceutical products byapplying the latest research from its own worldwide laboratories and fromcollaborations with eminent scientific organizations. Headquartered inIndianapolis, Ind., Lilly provides answers - through medicines and information- for some of the world's most urgent medical needs.Plavix(R)/Iscover(R) is a registered trademark of Sanofi Aventis Corp.P-LLYThis press release contains certain forward-looking statements about thepotential of the investigational compound prasugrel (CS-747, LY640315) andreflects Daiichi Sankyo's and Lilly's current beliefs. However, as with anypharmaceutical compound under development, there are substantial risks anduncertainties in the process of development and regulatory review.